A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease-Reference-Cited by-同舟云学术

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

Published:2015-08-03 Issue:30 Volume:6 Page:30408-30419
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

van Rhee Frits¹,Casper Corey²,Voorhees Peter M.³,Fayad Luis E.⁴,van de Velde Helgi⁵,Vermeulen Jessica⁶,Qin Xiang⁷,Qi Ming⁷,Tromp Brenda⁶,Kurzrock Razelle⁴

Affiliation:

1. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

3. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

4. MD Anderson Cancer Center, The University of Texas, Houston, TX, USA

5. Janssen Research & Development LLC, Beerse, Belgium

6. Janssen Research & Development LLC, Leiden, Netherlands

7. Janssen Research & Development LLC, Spring House, PA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival;Journal of Hematology & Oncology;2024-08-06

2. Red Cell Distribution Width Association with Subclinical Cardiovascular Disease in Patients with Rheumatoid Arthritis;Journal of Clinical Medicine;2023-10-12

3. A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report;Clinical Case Reports;2023-10

4. Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model;Polish Journal of Veterinary Sciences;2023-07-26

5. Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease;PharmacoEconomics - Open;2023-06-12